157 related articles for article (PubMed ID: 32627882)
1. Value of Precision Medicine in Advanced Non-Small Cell Lung Cancer: Real-World Outcomes Associated with the Use of Companion Diagnostics.
John A; Shah RA; Wong WB; Schneider CE; Alexander M
Oncologist; 2020 Nov; 25(11):e1743-e1752. PubMed ID: 32627882
[TBL] [Abstract][Full Text] [Related]
2. Trends in real-world biomarker testing and overall survival in US patients with advanced non-small-cell lung cancer.
Wu N; Ge W; Quek RG; Gleeson M; Pouliot JF; Dietz H; Jalbert JJ; Harnett J; Antonia SJ
Future Oncol; 2022 Dec; 18(39):4385-4397. PubMed ID: 36656547
[TBL] [Abstract][Full Text] [Related]
3. Clinical Impact of Adherence to NCCN Guidelines for Biomarker Testing and First-Line Treatment in Advanced Non-Small Cell Lung Cancer (aNSCLC) Using Real-World Electronic Health Record Data.
John A; Yang B; Shah R
Adv Ther; 2021 Mar; 38(3):1552-1566. PubMed ID: 33537872
[TBL] [Abstract][Full Text] [Related]
4. Associations Between Medicaid Insurance, Biomarker Testing, and Outcomes in Patients With Advanced NSCLC.
Gross CP; Meyer CS; Ogale S; Kent M; Wong WB
J Natl Compr Canc Netw; 2022 May; 20(5):479-487.e2. PubMed ID: 35545174
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis, testing, treatment, and outcomes among patients with advanced non-small cell lung cancer in the United States.
Yang M; MacEwan JP; Boppudi SS; McClain MR; O'Hara RM; Paik PK
Cancer Med; 2023 Dec; 12(24):21605-21614. PubMed ID: 38062905
[TBL] [Abstract][Full Text] [Related]
6. Association of Timely Comprehensive Genomic Profiling With Precision Oncology Treatment Use and Patient Outcomes in Advanced Non-Small-Cell Lung Cancer.
Yorio J; Lofgren KT; Lee JK; Tolba K; Oxnard GR; Schrock AB; Huang RSP; Brisbin L
JCO Precis Oncol; 2024 Mar; 8():e2300292. PubMed ID: 38452312
[TBL] [Abstract][Full Text] [Related]
7. Biomarker Testing, Treatment, and Outcomes in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Using a Real-World Database.
Bhandari NR; Hess LM; He D; Peterson P
J Natl Compr Canc Netw; 2023 Sep; 21(9):934-944.e1. PubMed ID: 37673115
[TBL] [Abstract][Full Text] [Related]
8. Patient Characteristics, Testing and Treatment Patterns, and Outcomes in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multinational, Real-World Study.
Molife C; Winfree KB; Bailey H; D'yachkova Y; Forshaw C; Kim S; Taipale KL; Puri T
Adv Ther; 2023 Jul; 40(7):3135-3168. PubMed ID: 37221352
[TBL] [Abstract][Full Text] [Related]
9. Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting.
Julian C; Pal N; Gershon A; Evangelista M; Purkey H; Lambert P; Shi Z; Zhang Q
BMC Cancer; 2023 Apr; 23(1):352. PubMed ID: 37069542
[TBL] [Abstract][Full Text] [Related]
10. Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis.
Hardtstock F; Myers D; Li T; Cizova D; Maywald U; Wilke T; Griesinger F
BMC Cancer; 2020 Mar; 20(1):260. PubMed ID: 32228520
[TBL] [Abstract][Full Text] [Related]
11. Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study.
Paz-Ares L; Gondos A; Saldana D; Thomas M; Mascaux C; Bubendorf L; Barlesi F
Lung Cancer; 2022 May; 167():41-48. PubMed ID: 35397297
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of a plasma-based comprehensive genomic profiling test in patients with non-small cell lung cancer in Korea.
Ahn BC; Lee S; Lee J; Lee JB; Hong MH; Lim SM; Jain S; Olsen S; Cho BC
Cancer Treat Res Commun; 2023; 36():100715. PubMed ID: 37307681
[TBL] [Abstract][Full Text] [Related]
13. Impact of Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced Non-Small-Cell Lung Cancer.
Sadik H; Pritchard D; Keeling DM; Policht F; Riccelli P; Stone G; Finkel K; Schreier J; Munksted S
JCO Precis Oncol; 2022 Oct; 6():e2200246. PubMed ID: 36315914
[TBL] [Abstract][Full Text] [Related]
14. Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers.
Ayers KL; Mullaney T; Zhou X; Liu JJ; Lee K; Ma M; Jones S; Li L; Redfern A; Jappe W; Liu Z; Goldsweig H; Yadav KK; Hahner N; Dietz M; Zimmerman M; Prentice T; Newman S; Veluswamy R; Wisnivesky J; Hirsch FR; Oh WK; Li SD; Schadt EE; Chen R
Oncologist; 2021 Jul; 26(7):e1226-e1239. PubMed ID: 33829580
[TBL] [Abstract][Full Text] [Related]
15. Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting.
Presley CJ; Tang D; Soulos PR; Chiang AC; Longtine JA; Adelson KB; Herbst RS; Zhu W; Nussbaum NC; Sorg RA; Agarwala V; Abernethy AP; Gross CP
JAMA; 2018 Aug; 320(5):469-477. PubMed ID: 30088010
[TBL] [Abstract][Full Text] [Related]
16. Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma.
Drakaki A; Dhillon PK; Wakelee H; Chui SY; Shim J; Kent M; Degaonkar V; Hoang T; McNally V; Luhn P; Gutzmer R
Oncoimmunology; 2020 Oct; 9(1):1824645. PubMed ID: 33101774
[TBL] [Abstract][Full Text] [Related]
17. Adherence to National Comprehensive Cancer Network ALK Testing Guidelines for Patients with Advanced Non-Small Cell Lung Cancer in U.S. Community Medical Centers.
Bernicker EH; Xiao Y; Abraham A; Yang B; Croix DA; Redpath S; Engstrom-Melnyk J; Shah R; Madala J; Allen TC
Oncologist; 2021 Jun; 26(6):e1050-e1057. PubMed ID: 33823082
[TBL] [Abstract][Full Text] [Related]
18. Real-World Impact of Comprehensive Genomic Profiling on Biomarker Detection, Receipt of Therapy, and Clinical Outcomes in Advanced Non-Small Cell Lung Cancer.
Wallenta Law J; Bapat B; Sweetnam C; Mohammed H; McBratney A; Izano MA; Scannell Bryan M; Spencer S; Schroeder B; Hostin D; Simon GR; Berry AB
JCO Precis Oncol; 2024 May; 8():e2400075. PubMed ID: 38754057
[TBL] [Abstract][Full Text] [Related]
19. Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes.
Stricker T; Jain N; Ma E; Yu E; Wang R; Schuldt R; Price R; Szado T; Sussell J; Ogale S; Lin V; Arrowsmith E; Slater D; Vaena D; Staszewski H; Fang B; Seneviratne L; Daniel D
Oncologist; 2024 Jun; 29(6):534-542. PubMed ID: 38417095
[TBL] [Abstract][Full Text] [Related]
20. Utilization Trends and Factors Associated With ROS1 Testing Among Patients With Advanced Non-small-cell Lung Cancer in US Community Practices.
Wong W; Wu N; Gupta R; Mansfield AS
Clin Lung Cancer; 2021 May; 22(3):e470-e480. PubMed ID: 32763067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
